In this article, Kate Barclay, Skills Strategy Consultant at BIA, outlines new changes to UK immigration law and how they will impact the life sciences sector. Prepared in collaboration with legal experts at Eversheds-Sutherland LLP.
In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.
Coulter Partners successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).
In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.
Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.
Their vanguard, breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics.
Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.
OK, I admit defeat. The UK government has published 3.5 key strategies that affect our sector in a week and I’m expecting at least two more in the coming days – a full analysis of so much text by today is beyond me but…
In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.
OutSee, announced it has secured £1.8 million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026
The average size of artificial intelligence (AI) deals was significantly higher than deals across the wider UK equity market in 2024, underlining the continued focus on the sector, reveals the British Business Bank’s annual Small Business Equity Tracker, published today.
Gastronomica, Pioneer Group’s cutting-edge food tech hub, was crowned winner of the Innovative Workplace Design award at the Property Week and Construction News Life Sciences & Research Clusters Awards.
The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.
